{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative adjective directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_9300", "batch_size": 200, "batch_pos": 148, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 2, "answer": "no", "rationale": "The segment reports stock price movement ('climbed' is moderate) and news factually.", "method": "llm_batch", "batch_id": "batch_2_17308", "batch_size": 200, "batch_pos": 112, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 3, "answer": "no", "rationale": "The segment discusses financial metrics ('climbed 2.4%') which are excluded from Q3.", "method": "llm_batch", "batch_id": "batch_3_14196", "batch_size": 200, "batch_pos": 22, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_15784", "batch_size": 200, "batch_pos": 8, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 5, "answer": "no", "rationale": "The segment reports a positive financial outcome and a potential development but lacks explicit calming language.", "method": "llm_batch", "batch_id": "batch_5_19124", "batch_size": 200, "batch_pos": 2, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 6, "answer": "no", "rationale": "The segment lists numbers but does not use a minimiser with scale contrast.", "method": "llm_batch", "batch_id": "batch_6_17524", "batch_size": 200, "batch_pos": 152, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 7, "answer": "no", "rationale": "The segment does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_15412", "batch_size": 200, "batch_pos": 132, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
{"Q": 8, "answer": "yes", "rationale": "Reports potential deal/funding for trial ('government is near a deal to fund a late-stage trial') as capability without active reassurance.", "method": "llm_batch", "batch_id": "batch_8_12408", "batch_size": 200, "batch_pos": 143, "statement_text": "Moderna shares climbed 2.4% premarket on Thursday after a report that the U.S. government is near a deal to fund a late-stage trial of the drugmaker's experimental mRNA bird-flu vaccine.", "article_id": 1648}
